Pharmacological and structure-activity relationship studies of oleoyl-lysophosphatidylinositol synthetic mimetics

Research output: Contribution to journalJournal articleResearchpeer-review

Metabolic diseases, such as obesity and type 2 diabetes, are relentlessly spreading worldwide. The beginning of the 21st century has seen the introduction of mechanistically novel types of drugs, aimed primarily at keeping these pathologies under control. In particular, an important family of therapeutics exploits the beneficial physiology of the gut-derived glucagon-like peptide-1 (GLP-1), with important clinical benefits, from glycaemic control to cardioprotection. Nonetheless, these protein-based drugs act systemically as exogenous GLP-1 mimetics and are not exempt from side effects. The food-derived lipid oleoyl-lysophosphatidylinositol (LPI) is a potent GPR119-dependent GLP-1 secreting agent. Here we present a structure-activity relationship (SAR) study of a synthetic library of oleoyl-LPI mimetics capable to induce the physiological release of GLP-1 from gastrointestinal enteroendocrine cells (EECs). The best lead compounds have shown potent and efficient release of GLP-1 in vitro from human and murine cells, and in vivo in diabetic db/db mice. We have also generated a molecular model of oleoyl-LPI, as well as its best performing analogues, interacting with the orthosteric site of GPR119, laying foundational evidence for their pharmacological activity.

Original languageEnglish
Article number105822
JournalPharmacological Research
Publication statusPublished - 2021

Bibliographical note

Publisher Copyright:
© 2021 Elsevier Ltd

    Research areas

  • Enteroendocrine cells, Glucagon-like peptide-1, GPR119, Oleoyl-lysophosphatidylinositol, Tetrazoles, Type 2 diabetes

ID: 281604312